Ligand id: 9175

Name: ripretinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 86.36
Molecular weight 509.09
XLogP 5.11
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

Bioactivity Comments
DCC-2618 inhibits mutant forms of KIT which are responsible for the development of resistance to current therapeutics, including mutants found in primary and treatment-resistant GIST. It also inhibits the KIT D816V mutation which drives development of some cases of mast cell neoplasms (mastocytosis). Patent WO2010051373 [1] contains preclinical evaluation of compounds claimed therein, but only provides 'binned' indications of binding affinities to target kinases, not precise IC50 values.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Affinity Units Concentration range (M) Reference
KIT proto-oncogene receptor tyrosine kinase Hs Inhibitor Inhibition - - - 1